Sandbox 127: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 33: | Line 33: | ||
== PBP2a | == B-Lactams that Inhibit PBP2a== | ||
MRSA becomes resistant to β-lactams by acquiring an alternative | MRSA becomes resistant to almost all β-lactams by acquiring an alternative TP, PBP2a, that is | ||
neither bound nor inhibited by β-lactams. Recently, two cephalosporins – | neither bound nor inhibited by β-lactams. Recently, two cephalosporins – | ||
<scene name='37/372724/Medicine_interaction/4'>cefobiprole</scene> and | <scene name='37/372724/Medicine_interaction/4'>cefobiprole</scene> and | ||
| Line 41: | Line 41: | ||
inhibit PBP2a because additional chemical groups at the | inhibit PBP2a because additional chemical groups at the | ||
<scene name='37/372724/Medicine_interaction/3'>R2</scene> | <scene name='37/372724/Medicine_interaction/3'>R2</scene> | ||
position of the | position of the ceftobiprole are able to interact with additional amino acid | ||
residues in PBP2a; specifically | residues in PBP2a; specifically | ||
<scene name='37/372724/Medicine_interaction/2'>Tyr446 and Met641</scene>. | <scene name='37/372724/Medicine_interaction/2'>Tyr446 and Met641, and increase the association of ceftobiprole with PBP2a</scene>. As such, ceftobiprole is (shown as colors of the atom types ([[CPK]]))is able to more efficiently react with <scene name='37/372724/R2_interaction/9'>Ser403</scene> and therefore inhibit the activity of PBP2a. | ||
